via Genetic Engineering and Biotechnology News
Understanding how drugs work is an important step in developing new treatments for COVID-19, says U of A virologist
A group of University of Alberta researchers who have discovered why the drug remdesivir is effective in treating the coronaviruses that cause Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) expect it might also be effective for treating patients infected with the new COVID-19 strain.
“Even if you know a drug works, it can be a red flag if you don’t know how it works,” said virologist Matthias Götte. “It is reassuring if you know exactly how it works against the target.
“We know the drug works against different coronaviruses, like MERS and SARS, and we know the novel coronavirus is very similar to SARS. So I would say I’m cautiously optimistic that the results our team found with remdesivir and MERS will be similar with COVID-19.”
The study, published in the Journal of Biological Chemistry this week, is among the first in Canada to discuss the COVID-19 strain.
Until now, there has not been a published explanation of why remdesivir may work against coronaviruses, said Götte, who added his study is an important step in answering that question.
Developed by Gilead Sciences as a response to the 2014 West African Ebola virus epidemic, remdesivir was first used on a patient with the novel coronavirus earlier this year in the United States.
As reported in the New England Journal of Medicine, the patient was given the drug on the seventh day of illness, and showed marked improvement the following day, with symptoms eventually disappearing altogether. And at a recent press conference in Beijing, the assistant director-general of the World Health Organization, Bruce Alyward, said remdesivir is the only drug available that may have real efficacy against COVID-19.
“What our study showed was that remdesivir essentially mimics one of the natural building blocks for RNA synthesis necessary for genome replication of the virus. Enzymes within the virus are synthesizing the viral RNA genome with these building blocks, but they mix up the bits they need with the drug. Once the drug is incorporated into the growing RNA chain, the virus can no longer replicate,” explained Götte.
He said the next step is to wait for results from ongoing clinical trials with remdesivir, which are expected by the end of April. Even then, that won’t be the end of the story, he cautioned.
“It’s likely we’ll need more than one drug to properly fight emerging diseases like COVID-19, as we have with HIV and hepatitis C virus infections,” Götte said.
“Ideally, we will have a couple of drugs because certain strains could be resistant to certain treatments.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19
- Class of 2024 reflects on college years marked by COVID-19, protests and life’s lost milestones
The unrest at campuses over the Israel-Hamas war has marked an emotional end to the college experiences of those graduating in 2024 that started amid a pandemic.
- Disgraced ex-NY Gov. Andrew Cuomo agrees to testify before House COVID-19 panel
Disgraced former New York Democratic Gov. Andrew Cuomo has agreed to appear before a panel of House lawmakers and discuss his administration’s controversial handling of the COVID-19 pandemic in New ...
- ‘They’re never forgotten’: Brooklyn cemetery unveils COVID-19 memorial
Green-Wood Cemetery in Brooklyn is unveiling a new COVID memorial, offering a space for remembrance and solace to those who lost loved ones during the pandemic. Gustavo Padilla, a gravedigger at Green ...
- Andrew Cuomo agrees to testify to Congress on Covid-19 nursing home advisory
Former New York Gov. Andrew Cuomo, after being subpoenaed last month, has agreed to testify to Congress about his controversial nursing home advisory from the early days of the Covid-19 pandemic, Rep.
- CDC encourages older adults to get additional COVID-19 vaccine dose
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25.
Go deeper with Google Headlines on:
COVID-19
[google_news title=”” keyword=”COVID-19″ num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Coronaviruses
- Class of 2024 reflects on college years marked by COVID-19, protests and life’s lost milestones
The unrest at campuses over the Israel-Hamas war has marked an emotional end to the college experiences of those graduating in 2024 that started amid a pandemic.
- Disgraced ex-NY Gov. Andrew Cuomo agrees to testify before House COVID-19 panel
New York’s comptroller found that Cuomo had “misled the public” in undercounting such deaths by more than 50%.
- ‘They’re never forgotten’: Brooklyn cemetery unveils COVID-19 memorial
Green-Wood Cemetery in Brooklyn is unveiling a new COVID memorial, offering a space for remembrance and solace to those who lost loved ones during the pandemic. Gustavo Padilla, a gravedigger at Green ...
- Andrew Cuomo agrees to testify to Congress on Covid-19 nursing home advisory
Former New York Gov. Andrew Cuomo, after being subpoenaed last month, has agreed to testify to Congress about his controversial nursing home advisory from the early days of the Covid-19 pandemic, Rep.
- COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent ...
Go deeper with Google Headlines on:
Coronaviruses
[google_news title=”” keyword=”coronaviruses ” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]